Medunik Canada signs an exclusive agreement with HRA pharma for commercialization of Lysodren® (mitotane) in Canada, for the treatment of inoperable adrenal cortical carcinomas
BLAINVILLE, QC (CANADA), January 16, 2019 — Medunik Canada, a company dedicated to improving the health and quality of life of Canadians living with rare diseases, is proud to announce the signing of a licensing and supply agreement with HRA Pharma. The agreement grants Medunik Canada exclusive commercial rights in Canada for Lysodren®, indicated for the treatment of inoperable functional and non-functional adrenal cortical carcinoma.